Current Report · Items 5.02 · 8-K/A
Bausch + Lomb Corporation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 6, 2026, Bausch + Lomb Corporation (the “Company”) filed a Current Report on Form 8-K (the “Initial 8-K”) regarding the resignation of certain members of its board of directors (the “Board”) and the appointment of Thomas J.…
Filed Aug 12, 2026Accepted Aug 12, 2026, 7:01 AM EDTCIK 1860742Accession 0000950103-26-012223
Company context
Our mission is simple - we help people see better to live better, all over the world. For nearly two centuries we’ve evolved with the changing needs of patients and customers, and our commitment to innovation and improving the standard of care in eye health has never been stronger. From contact lenses to prescription products, over-the-counter options, surgical devices and more, we’re turning bold ideas into better outcomes through passion, perseverance and purpose. Learn more at www.bausch.com and connect with us on Facebook, Instagram, LinkedIn, X and YouTube.
Current securities
Disclosure sections
Items 5.02Select an item to read the extracted section. The as-filed document remains the primary evidence.
Item 5.02Item 5.02 - Departure/Election of Directors
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers.
On August 6, 2026, Bausch + Lomb Corporation (the “Company”)
filed a Current Report on Form 8-K (the “Initial 8-K”) regarding the resignation of certain members of its board of directors
(the “Board”) and the appointment of Thomas J. Appio, Robert Chersi, Laurence Paul, M.D. and Barbara Trebbi to the Board,
effective August 5, 2026. This Amendment No. 1 to the Initial 8-K is being filed to report that as of August 10, 2026, Mr. Appio has succeeded
Brent Saunders in his capacity as Chairman of the Board, with Mr. Saunders continuing to serve as a member of the Board. As of August
10, 2026, the Board has also appointed Dr. Paul to serve as Lead Independent Director. Additionally, on August 10, 2026, the Board appointed
Mr. Chersi as a member of its Audit and Risk Committee and Talent and Compensation Committee, Dr. Paul as a member of its Nominating and
Corporate Governance Committee and Science and Technology Committee, John A. Paulson as chair of its Nominating and Corporate Governance
Committee, Eduardo Alfonso, M.D. as chair of its Science and Technology Committee and Ms. Trebbi as chair of its Talent and Compensation
Committee, each appointment effective August 10, 2026.
Following the resignations, appointments and committee assignments
described above, as well as certain other updates to the Board’s committees, the Board’s committees are now comprised as follows:
Audit and Risk Committee: Sarah B. Kavanagh (Chair), Robert J. Chersi and Russel C. Robertson
Science and Technology Committee: Eduardo Alfonso, M.D. (Chair), Nathalie Bernier and Laurence Paul, M.D.
Nominating and Corporate Governance Committee: John A. Paulson (Chair), Sarah B. Kavanagh and Laurence Paul, M.D.
Talent and Compensation Committee: Barbara J. Trebbi (Chair), Robert J. Chersi and Russel C. Robertson
